Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31587768 | 1.00 | GABRA1 (0.43) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| Hydrochloric Acid SCHEMBL2864529 | 0.98 | LMNA (0.41) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL59823 | 0.86 | GABRA1 (0.50) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL20459466 | 0.79 | ESR1 (0.31) | ESR1 | |
| SCHEMBL1107763 | 0.78 | CYP2A6 (0.45) | TSHRCYP1A2CA1CA2ALDH1A1 | |
| SCHEMBL24497702 | 0.77 | POLB (0.39) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL30154737 | 0.77 | GABRA1 (0.41) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL26127801 | 0.77 | GABRA1 (0.41) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL24012474 | 0.77 | GABRA1 (0.41) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL24445129 | 0.76 | GABRA1 (0.38) | GABRA1LMNAGABRG2GABRB3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | 1ST Biotherapeutics, Inc. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9968921-B2 | Ethylene oligomerization catalyst systems using chemically-treated solid oxides | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170341068-A1 | Ethylene Oligomerization Catalyst Systems Using Chemically-Treated Solid Oxides | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2017-11-30 | — | — | US | disclosed |
| US-9707549-B1 | Ethylene oligomerization catalyst systems using chemically-treated solid oxides | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2017-07-18 | — | — | US | disclosed |
| EP-0942006-B1 | Catalyst for olefin polymer production and process for olefin polymer production employing the catalyst | TOSOH CORP (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-0849292-B1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORP (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-6372681-B1 | METALLOCENE OF TRANSITION METAL AND; METAL OXIDE, SULFIDE, PHOSPHIDE, CARBIDE, NITRIDE, AND/OR SELENIDE; ORGANOALKALINE EARTH OR ZINC COMPOUND; AND ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6337297-B1 | CHROMIUM CATALYST FOR TRIMERIZATION OF ETHYLENE WITH MULTIDENTATE LIGAND OR HALOGEN, CARBOXY GROUP | TOSOH CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6110858-A | AN OLEFIN POLYMERIZATION CATALYST CONSISTS OF A TRANSITION METAL COMPOUND, A MODIFIED CLAY COMPOUND CONTAINING CLAY MINERAL AND AN AMINE COMPOUND AND AN ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0942006-A2 | Catalyst for olefin polymer production and process for olefin polymer production employing the catalyst | TOSOH CORPORATION (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0849292-A1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORPORATION (JP) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170341068-A1 | Ethylene Oligomerization Catalyst Systems Using Chemically-Treated Solid Oxides | NOD2, OR51E2, OSTC | GABRA1 3238/4885LMNA 4340/4885GABRG2 2301/4885 |
| US-20230365557-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885LMNA 1809/4885GABRG2 1015/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885LMNA 3372/4885GABRG2 4029/4885 |
| US-11802126-B2 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | SMN1; SMN2, SNCA, HTT | GABRA1 395/4885LMNA 1809/4885GABRG2 1015/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885LMNA 3372/4885GABRG2 4029/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885LMNA 3372/4885GABRG2 4029/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885LMNA 3372/4885GABRG2 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.